History
Explore our Journey of Excellence in Pharmaceutical Manufacturing.
Tianming Pharmaceuticals: to be a global pharmaceutical leader driven by innovation
Tianming Pharmaceuticals is a high-tech enterprise focusing on the research and development, production and sales of new drugs. Our company owns three major production bases as well as two major R&D centers. In addition, the company has established sales subsidiaries in India and Bangladesh, and has established extensive business contacts with partners in many countries around the world.
In the field of R&D, Tianming Pharmaceuticals has a R&D team of more than 100 professional talents, dedicated to the research and development of antibiotics and diabetes drugs, and its R&D level is in a leading position in China. Our company has unique technical advantages in the production process of pharmaceutical raw materials and intermediates, and has passed the ISO9001 international quality system certification, ensuring high standards and continuous innovation of product quality.
Our Development History
Our Culture
Corporate Vision
To develop innovative medicines and realize the dream of health
Corporate Mission
To contribute to the healthy life of human society while pursuing the material and spiritual happiness of all employees
Corporate Values
Honesty and Trustworthiness, Unity and Mutual Assistance, Pragmatism and Responsibility, Innovation and Progress
What's News
Latest news at Tianming
Finerenone Mechanism of Action: A Non-Steroidal MRA Built Differently
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Clascoterone vs Minoxidil: How They Actually Compare for Hair Loss
Clascoterone vs minoxidil: Compare mechanisms, Phase 3 trial data, side effects, and whether they work better together. Evidence-based overview for hair loss.
Finerenone vs Spironolactone: A Head-to-Head Look at Safety and Efficacy
Finerenone vs spironolactone: head-to-head real-world data shows finerenone has 69% lower mortality, 53% fewer kidney events, and less hyperkalemia. Nonsteroidal MRA with no hormonal side effects.